Summary.-Extracts of ovine squamous-cell carcinoma (OSCC) prepared by different procedures, were injected at varying concentrations into 184 tumour-bearing sheep. At a total protein of 0X5 mg and greater, there was significant enhancement and metastasis in all 120 sheep examined. Extracts of OSCC containing less than 0.5 mg protein, or of human squamous-cell carcinoma and normal sheep skin containing high levels of protein, had no effect on subsequent tumour development. Extracts of foetal sheep skin at the 3mg-protein level produced significant enhancement and metastasis. The degree of enhancement was inversely proportional to the developmental stage of the tumour at the time of treatment.
WHILST immunotherapy of neoplastic disease has been practised for many decades (Muggia, 1977) only of recent years has the immunological basis of such immunotherapy been clarified (Woodruff, 1964; Baldwin and Price, 1976) . Bluming (1975) , Nelson (1974) and Baldwin and Price (1976) have described the association of tumour-associated antigens with partial immunity to individual tumours, and have outlined the association of such antigens with immunity-blocking factors. Kahan (1973) and Kahan and Pellis (1975) have described the biological criteria in the use of fresh subcellular tumour extracts for specific immunoprotection, and as therapeutics.
Successful immunotherapy trials have been reported in haemopoietic disease of humans and rodents (Mathe, 1971; Parr 1972) , in bovine squamous-cell carcinoma (van Kampen et al., 1973; Spradbrow et al., 1977) , and in some solid tumours of humans (Hughes et al., 1970) . The need for careful evaluation of immunotherapeutic treatment has been shown by Spradbrow et al. (1977) who obtained regression of bovine squamous-cell carcinoma with single treatments, but enhancement with multiple treatments.
Ovine squamous-cell carcinoma (OSCC) is a relatively common lesion in the tropical zones of Australia, occurring as a solar keratosis in an average of 300 of sheep (Ladds and Entwistle, 1977) . The gross and histopathological features of this tumour have been described in detail (Lloyd, 1961; Ladds and Entwistle, 1977) .
The present communication describes the results of immunotherapy of OSCC, using a range of tumour extracts with varying total protein contents.
MATERIALS AND METHODS
Preparation of antigen (tumour extracts).-Biopsied tumours were sliced into 5mm sections, and held at 4°C in phosphate-buffered saline, pH 7-2 (PBS) for up to 4 h before processing. Tumour slices were trinmmed of dead tissue and skin, and were finely minced. The suspension was then forced through a 60-mesh stainless-steel sieve and the cell suspensions obtained were tested by trypan-blue exclusion for viability. In all cases cell viability ranged from 75%o to 90o%.
Cell suspensions were then snap-frozen in liquid N2 to form a cake, which was pulver-ized in a locally manufactured stainless-steel tissue homogenizer. Powdered tissues were then treated as below.
(a) Ultrasonication (u/s TA).-One part of tumour tissue in 4 parts of chilled PBS was ultrasonicated at 20-25 kV/s for 4 min in an MSE 100-watt ultrasonic disintegrator. Sonicated suspensions were filtered through cotton wool and 60-mesh copper sieves. These extracts were frozen and thawed twice before use.
(b) 2m NaCI tumour extracts (2M NaCI TA). -One part of powdered tumour and 4 parts of 2M NaCl were stirred at 4°C for 16 h, and then clarified by centrifugation at 4500 g for 20 min. The supernatant fluids were then dialysed x 3 against 200 volumes of PBS at 4°C over 36 h. The dialysate was then centrifuged at 70,000 g for 3 h in a refrigerated centrifuge, the supernatant, representing soluble extract, being stored at -20°C before use.
(c) 3M KCl tumour extracts (3MKCO TA).-The procedure used was a modified version of that described by Kahan and Pellis (1975) as outlined for 2M NaCl extracts above.
(d) DNA-enriched tumour extracts.-A modification of the technique described by Kirby (1957) was used. One part of powdered tumour was stirred in 4 volumes of 6% sodium p-amino-salicylate, whilst 5 volumes of 90% phenol (w/w) was quickly added. After stirring at 4°C for 2 h, the mixture was centrifuged at 2500 g for 30 min, and the supernatant collected. This was then dialysed and centrifuged at 70,000 g for 3 h as described above.
(e) Saline-phenol extracts.-Slight modification of the technique described by Spradbrow et al. (1977) was used. One part of powdered tumour was minced with 2 parts of 0415M NaCl and 2 parts of freshly distilled phenol. After clarification at 70,000 g for 30 min, the aqueous phase and interface were pooled, and dialysed as above (or ether extracted) to remove excess phenol. Finally high-speed centrifugation was carried out as above.
Control antigens were prepared in a similar manner to the above.
Antigen administration.-Protein concentration of inocula was adjusted as required, using an SP 800A UV spectrophotometer (UNICAM) at 280 nm, and results were checked by the technique described by Lowry et al. (1951) were lost from all groups during the 7 months experimental period.
Animals on test were observed at 2, 4, 8, 16, 24 and 28 weeks post injection (p.i.) and were then killed for autopsy. At each examination tumours were photographed and measured, and blood samples were taken for subsequent serology. Biopsy samples or tissues taken at necropsy, were fixed in 10% buffered formalin, embedded in paraffin and stained with haematoxylin and eosin (H. and E.), and Ayoub-Shklar technique for keratin and prekeratin (Luna, 1968) .
Measurement of tumour volume.-Tumour volume (cm3) was calculated in each case by caliper measurement (Mitutoyo Co., Japan). This was done by either measurement of the base area of the tumour multiplied by height in cm for conical tumours, or estimation of the volume of non-conical tumours by measuring the central width in two constant planes and multiplying by the depth. Photography of each tumour at the time of examination enabled a rough check on volume from the photographs.
Tumour growth was calculated from the following formula:
Percentage (%) of tumour growth= Tumour volume _ Tumour volume after treatment before treatment x 100
Tumour volume before treatment Statistical analysis.-Percentages of tumour growth were transformed to logarithms and analysed by a 2-way (stage X antigen) analysis of variance. Differences between comparisons were considered significant if P<0 05.
Throughout the text, means ±s.e. are quoted.
RESULTS

Control groups
In the 22 OSCC sheep which received no inoculation, the tumours developed slowly and regularly over the 24-week observation period (88 4+3 9%). In the control groups receiving 0 15M saline-phenol or 3M KCI extracts containing 3 mg of total protein from normal sheep skin, from DNA-enriched extract of human squamous-cell carcinoma, or of CFA alone, there was no significant difference in growth from the uninoculated group (P> 0.05, Fig. 1 ). The group inoculated with 3M KCI extract of ovine foetal skin containing 3 mg total protein showed significant enhancement of growth in comparison to other controls (P<0 0005, Fig. 1 (0-15M and 2M) tumourextracts (Fig. 4) Fig. 3 ). 
Macroscopic and microscopic observrations
Macroscopic changes in an enhanced tumour are shown in Fig. 6 , and distribution of metastases in Table II Study of lymphatic vessels in dermis and subcutis of neoplastic skin, parotid lymph nodes, mandibular lymph nodes and lung were made in all cases. Frequent involvement of lymphatic vessels with characteristic tumour were noted in enhanced animals where spread to local lymph nodes occurred (Table II) .
DISCUSSION
The purpose of this preliminary work was to attempt duplication with OSCC of the successful trials of van Kampen et al. (1973) , and subsequently of Spradbrow et al. (1977) in immunotherapy of bovine squamous-cell carcinoma.
Although van Kampen et al. (1973) tracts successfully, but again gave no details of any adjustment or calculation of protein content of preparations.
In the present series of trials there was an obvious relationship between the protein content of inocula and their effect on the tumour. At a level of. 0 01 mg of protein, no change in tumour development in comparison to controls occurred. At 0 5 mg protein, enhancement of tumour occurred, this enhancement increasing directly with increase in concentration of protein. Associated with enhancement, there was a parallel increase in the frequency of metastases in lymphatic vessels draining the lesion, in local lymph nodes and in lung. The extract preparation described by Spradbrow et al. (1977) gave with OSCC extracts very high levels of protein which were associated with enhancement and metastases in sheep. It would seem that a very different response to immunotherapy occurs in bovine squamous-cell carcinoma from that observed with OSCC.
Whilst there were differences in degree of enhancement with different types of extract, this could not be related to the gross protein content of the extract, as all extracts were adjusted to the same overall protein levels. OSCC tumour extracts have been shown to contain quantitatively one major and 2 minor proteins (Jun, Maguire and Johnson, unpublished observation). It is possible that the different types of extraction procedure may give differing proportions of these proteins. It is possible that one of these proteins at least is a foetal antigen, as a degree of enhancement was noted with extracts of foetal lamb skin.
As yet, insufficient data are available to attempt an explanation of the mechanisms involved in enhancement of OSCC by tumour extracts. Symes (1974) and Baldwin and Price (1976) associate enhancement after immunotherapy with an increase in circulating antibody/antigen complexes (blocking factors). It is, however, difficult to believe that the relatively small amounts of protein injected would be any more efficient in modifying the immune response than the bulk of antigen associated with the growing tumour. Further work on the mechanism of enhancement is in progress.
